TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32195897

Group type: EXPERIMENTAL
Intervention: Rapid escalation to enteral nutrition reaching goal feeds by 27 hours
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard feeding practice reaching goal feeds by 63 hours
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rapid escalation to enteral nutrition
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard feeding practice
Number of subjects: 50
Study: 35500476

Group type: EXPERIMENTAL
Intervention: New room (birthing room designed with person‐centred considerations)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Regular room
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: New room
Number of subjects: 406
Study: 34881909

Group type: EXPERIMENTAL
Intervention: Competence feedback group (CFG)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 114
Study: 32740291

Group type: EXPERIMENTAL
Intervention: Noncaloric placebo (PLA)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 6.4% maltodextrin (CHO) solution
Number of subjects: 36

Group type: COMPARATOR
Intervention: Water (WAT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All treatments (WAT, PLA, CHO)
Number of subjects: 36
Study: 33296380

Group type: EXPERIMENTAL
Intervention: Circulating sphingolipids (specifically ceramides and sphingomyelins)
Number of subjects: 1974

Group type: EXPERIMENTAL
Intervention: Saturated sphingomyelins
Number of subjects: 1974

Group type: EXPERIMENTAL
Intervention: 13 sphingolipids
Number of subjects: 1974

Group type: EXPERIMENTAL
Intervention: Genetically instrumented ceramide (d18:1/20:1)
Number of subjects: 1974
Study: 35748295

Group type: EXPERIMENTAL
Intervention: Corrected insulin response (CIR)
Number of subjects: 0
Study: 33141785

Group type: EXPERIMENTAL
Intervention: Dance/Movement Therapy (DMT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Verbal Treatment as Usual (TAU)
Number of subjects: 32
Study: 32427935

Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (ID) program
Number of subjects: 46

Group type: COMPARATOR
Intervention: Home-based (HB) exercise program
Number of subjects: 46
Study: 35593501

Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation (single oral tablet of soy extract for 30 days)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Estradiol treatment (0.5 μg subcutaneous injection in sesame oil for 30 days)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (subcutaneous injections of vehicle and oral placebo for 30 days)
Number of subjects: 15
Study: 33374975

Group type: EXPERIMENTAL
Intervention: Milk-based infant formula with micronutrients and PUFAs
Number of subjects: 2

Group type: COMPARATOR
Intervention: Milk-based infant formula with micronutrients, no PUFAs added
Number of subjects: 2
Study: 36422887

Group type: EXPERIMENTAL
Intervention: Experimental messages (31 total, including 25 experimental and 6 control messages)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control messages (6 total)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Experimental messages (themes 2-5)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Messages providing scientific evidence from credible sources
Number of subjects: 189
Study: 33269417

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 32074780

Group type: EXPERIMENTAL
Intervention: Dural puncture epidural group (group D)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Epidural analgesia group (group P)
Number of subjects: 100
Study: 36259428

Group type: EXPERIMENTAL
Intervention: Cerebellar transcranial direct current stimulation (tDCS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 34724345

Group type: EXPERIMENTAL
Intervention: Tolebrutinib 5 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tolebrutinib 15 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tolebrutinib 30 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tolebrutinib 60 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tolebrutinib 120 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tolebrutinib 7.5 mg (multiple ascending dose)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tolebrutinib 15 mg (multiple ascending dose)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tolebrutinib 30 mg (multiple ascending dose)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tolebrutinib 60 mg (multiple ascending dose)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tolebrutinib 90 mg (multiple ascending dose)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 33475318

Group type: EXPERIMENTAL
Intervention: CT model
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Radiomic model
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Combination model
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Nomogram based on combination model
Number of subjects: 200
Study: 32789987

Group type: EXPERIMENTAL
Intervention: In-person experience (Live Animal) viewing a polar bear training session for 10 minutes
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Video experience (Video Animal) watching a video of the polar bear training session
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (Control) listening to audio from the live experience while viewing an image of an animal care specialist
Number of subjects: 124
Study: 35853583

Group type: EXPERIMENTAL
Intervention: Prostaglandin use for induction of labor
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Cesarean delivery
Number of subjects: 941
Study: 32919897

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided dextrose prolotherapy (2 cc dextrose 20% injection, 2 sessions)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Radial extracorporeal shock wave therapy (ESWT, 3 sessions)
Number of subjects: 59
Study: 32571284

Group type: EXPERIMENTAL
Intervention: Single Task (ST)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Verbal Dual-Task (DT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Auditory Dual-Task (DT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Motor Dual-Task (DT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Visual Dual-Task (DT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy Group (HG)
Number of subjects: 40
Study: 33973838

Group type: EXPERIMENTAL
Intervention: Gray and white matter involvement
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Corticospinal tract involvement
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Territorial infarcts
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Infarct confinement to gray matter, corticospinal tract sparing, and scattered infarct structure
Number of subjects: 1026
Study: 32719096

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1605

Group type: COMPARATOR
Intervention: Intensive medical therapy (IMT)
Number of subjects: 1605

Group type: EXPERIMENTAL
Intervention: Random deferral of PCI (simulated)
Number of subjects: 1605
Study: 35681620

Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg QD)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pasireotide-LAR (60 mg Q4 weeks)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combination of Everolimus and Pasireotide-LAR
Number of subjects: 42
Study: 32525975

Group type: EXPERIMENTAL
Intervention: Progressive strength training with elastic resistance (2 days per week for 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual daily activities
Number of subjects: 20
Study: 35086041

Group type: EXPERIMENTAL
Intervention: 200-ppb ozone exposure for 2 hours
Number of subjects: 32
Study: 33428870

Group type: EXPERIMENTAL
Intervention: 2 + 1 schedule of the 13-valent pneumococcal conjugate vaccine (PCV13) with 4CMenB at 2, 4, and 12 months of age.
Number of subjects: 213

Group type: COMPARATOR
Intervention: 1 + 1 schedule of the 13-valent pneumococcal conjugate vaccine (PCV13) with 4CMenB at 3 and 12 months of age.
Number of subjects: 213
Study: 35877183

Group type: EXPERIMENTAL
Intervention: Multifocal soft contact lenses (MFSCLs)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Orthokeratology contact lenses (Ortho-kCLs)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Single vision spectacles (SVSs)
Number of subjects: 66
Study: 34135111

Group type: COMPARATOR
Intervention: Daily energy restriction (75:75)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intermittent fasting (0:150)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fasting without energy restriction (0:200)
Number of subjects: 36

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 36
Study: 32087394

Group type: EXPERIMENTAL
Intervention: Simulator-based high order training program
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control group (waiting group)
Number of subjects: 183
Study: 35792962

Group type: EXPERIMENTAL
Intervention: 2 g amoxicillin administered 1 hour before surgery, followed by 1.5 g each for the first 3 postoperative days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 0
Study: 34011108

Group type: EXPERIMENTAL
Intervention: Myofascial release (3 sessions of 50 minutes over 3 weeks)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 69
Study: 36200390

Group type: EXPERIMENTAL
Intervention: Expanded Intervention (Delaware PEAK) - five 45- to 60-minute video conference-based sessions of supervised exercise delivered over 12 weeks by a physical therapist.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Brief Intervention (control group) - a website with prerecorded videos directing participants to web-based resources for strengthening, physical activity, and pain management for knee OA.
Number of subjects: 100
Study: 33534047

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP) 40 mg bid for 3 days followed by 20 mg bid for 3 days
Number of subjects: 64
Study: 32155883

Group type: EXPERIMENTAL
Intervention: DHA supplementation (1250 mg daily for 12 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Healthy controls with DHA
Number of subjects: 31
Study: 35511621

Group type: EXPERIMENTAL
Intervention: Manual reduction (Group A)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Automatic device reduction (Group B)
Number of subjects: 202
Study: 32394655

Group type: EXPERIMENTAL
Intervention: Acupuncture (tongdu jiangni needling technique), 3 times a week for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Omeprazole enteric capsules (OME), 20 mg twice a day for 8 weeks
Number of subjects: 60
Study: 34932889

Group type: EXPERIMENTAL
Intervention: Internet+Incentives
Number of subjects: 418

Group type: COMPARATOR
Intervention: Internet-Only
Number of subjects: 418
Study: 33707523

Group type: EXPERIMENTAL
Intervention: HeartMan mobile personal health system
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study: 36065641

Group type: EXPERIMENTAL
Intervention: Verbatim repetition
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Isomorphic changes
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Total revisions
Number of subjects: 46
Study: 33561214

Group type: EXPERIMENTAL
Intervention: SQ-LNS (800 μg RE/20g) during pregnancy and the first 6 mo postpartum; children received SQ-LNS (400 μg RE/20 g) from 6 to 18 mo of age.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiple micronutrients (MMN; 800 μg retinol equivalent (RE)/capsule) during pregnancy only.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iron and folic acid (IFA) during pregnancy only.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SQ-LNS (400 μg RE/20 g) for children from 6 to 18 mo of age.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiple micronutrients (MMN) and Iron and folic acid (IFA) for children (no supplement).
Number of subjects: 0
Study: 32613240

Group type: EXPERIMENTAL
Intervention: Physiologic E2 (∼180 pg/ml) with P4 10 mg/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Moderately supraphysiologic E2 (600-800 pg/ml) with P4 10 mg/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Supraphysiologic E2 (2000 pg/ml) with P4 10 mg/day
Number of subjects: 10
Study: 34996663

Group type: EXPERIMENTAL
Intervention: Tooth-borne expander (hyrax)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Bone-borne expander (computer-guided miniscrew-supported)
Number of subjects: 36
Study: 33766497

Group type: EXPERIMENTAL
Intervention: BH4 treatment
Number of subjects: 11

Group type: COMPARATOR
Intervention: Diet only (without BH4)
Number of subjects: 11
Study: 34214362

Group type: EXPERIMENTAL
Intervention: Centella asiatica cream applied twice a day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ceramide cream applied twice a day
Number of subjects: 30
Study: 32556156

Group type: EXPERIMENTAL
Intervention: Pneumatic Retinopexy (PnR)
Number of subjects: 160
Study: 34939269

Group type: EXPERIMENTAL
Intervention: Intervention group (received intervention immediately)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Delayed intervention control group (received intervention later)
Number of subjects: 52
Study: 33025927

Group type: EXPERIMENTAL
Intervention: Toothpaste containing REFIX technology (Regenerador + Sensitive DentalClean, Rabbit Corp)
Number of subjects: 53
Study: 35407373

Group type: EXPERIMENTAL
Intervention: Virtual Reality Rehabilitation System (VRRS)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (illustrated booklet)
Number of subjects: 43
Study: 32441474

Group type: EXPERIMENTAL
Intervention: Combined Hormonal Contraceptive (CHC) users
Number of subjects: 170

Group type: COMPARATOR
Intervention: Non-Combined Hormonal Contraceptive (non-CHC) users
Number of subjects: 170
Study: 34817733

Group type: EXPERIMENTAL
Intervention: Competing risks joint model (CR JM)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Standard joint model (SJM)
Number of subjects: 267
Study: 33081849

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 400 mg twice on first day followed by 400 mg daily for 10 days + Ribavirin (1.2 g loading dose followed by 600 mg every 12 hours for 10 days) + Standard Treatment (STNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Treatment (STNS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lopinavir (200 mg) + Ritonavir (50 mg) two tablets twice daily + Ribavirin (1.2 g loading dose followed by 600 mg every 12 hours for 10 days) + Standard Treatment (STs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 400 mg twice on first day followed by 400 mg daily for 10 days + Ribavirin (1.2 g loading dose followed by 600 mg every 12 hours for 10 days) + Standard Treatment (STs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Treatment (STs)
Number of subjects: 0
Study: 36277985

Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Lithotripsy (ESWL)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 90
Study: 32977992

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 62
Study: 32450838

Group type: EXPERIMENTAL
Intervention: Regular treatment interval cohort (3 initial monthly IVT-AFL injections followed by regular injections every 2 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irregular treatment interval cohort with initial doses (3 initial monthly IVT-AFL injections)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irregular treatment interval cohort without initial doses
Number of subjects: 0
Study: 33104981

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray 55 μg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group without intranasal steroid
Number of subjects: 83
Study: 34942176

Group type: EXPERIMENTAL
Intervention: BF-based circulatory management
Number of subjects: 439

Group type: COMPARATOR
Intervention: BP-based circulatory management (Control)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Low blood flow (BF)
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Low blood pressure (BP)
Number of subjects: 439
Study: 33835666

Group type: EXPERIMENTAL
Intervention: Immuno-oncology (IO) based systemic treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study: 32098739

Group type: EXPERIMENTAL
Intervention: Individually-tailored educational videos about maternal and infant vaccines and the cocooning strategy
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Intention to receive maternal influenza vaccine, perceived safety of maternal Tdap vaccine, perceived efficacy of maternal influenza vaccine, perceived susceptibility to and severity of influenza during pregnancy, trust in vaccine information from CDC and academic institutions
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: Uncertainty about infant vaccine intentions
Number of subjects: 1095
Study: 34581452

Group type: EXPERIMENTAL
Intervention: Cryopreserved platelets
Number of subjects: 89

Group type: COMPARATOR
Intervention: Liquid-stored platelets
Number of subjects: 89
Study: 33650471

Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed (154 patients, 38.1%)
Number of subjects: 404

Group type: COMPARATOR
Intervention: No antibiotics prescribed (250 patients, 61.9%)
Number of subjects: 404
Study: 32580883

Group type: COMPARATOR
Intervention: 27 Gy in five fractions (over 1 week)
Number of subjects: 4096

Group type: COMPARATOR
Intervention: 26 Gy in five fractions (over 1 week)
Number of subjects: 4096

Group type: EXPERIMENTAL
Intervention: 40 Gy in 15 fractions (over 3 weeks)
Number of subjects: 4096
Study: 35830133

Group type: EXPERIMENTAL
Intervention: Nano-suspension of Talaromyces flavus at concentrations of 1, 4, and 5 per thousand (soil addition method)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nano-powder of Talaromyces flavus at concentrations of 2 and 3 per thousand (soil addition method)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Registered formulation of Talaromin (seed impregnation and soil addition methods)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 16

Group type: COMPARATOR
Intervention: Infected control
Number of subjects: 16
Study: 34089600

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (12 weeks of physical exercise training and five psycho‐educational consultations)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (exploratory outcomes)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control (usual care without rehabilitation)
Number of subjects: 117
Study: 33082342

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine therapy (400 mg twice daily for seven days)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 53
Study: 35153119

Group type: COMPARATOR
Intervention: Neostigmine (0.05 mg/kg) + Atropine (0.02 mg/kg)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Sugammadex (1 mg/kg) after Neostigmine
Number of subjects: 98
Study: 34600264

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg twice daily
Number of subjects: 108

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 108
Study: 32811690

Group type: EXPERIMENTAL
Intervention: Front-of-pack labelling and regulated nutrition claims
Number of subjects: 0
Study: 33685776

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) antimicrobials
Number of subjects: 56

Group type: COMPARATOR
Intervention: Oral (PO) antimicrobials
Number of subjects: 56
Study: 35091076

Group type: EXPERIMENTAL
Intervention: CT+/MSC-
Number of subjects: 4119

Group type: EXPERIMENTAL
Intervention: CT+/MSC+
Number of subjects: 4119

Group type: COMPARATOR
Intervention: CT-/MSC-
Number of subjects: 4119

Group type: EXPERIMENTAL
Intervention: CT-/MSC+
Number of subjects: 4119
Study: 33677046

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Baseline
Number of subjects: 570
Study: 34507611

Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 602

Group type: COMPARATOR
Intervention: Foley catheter
Number of subjects: 602
Study: 33395979

Group type: EXPERIMENTAL
Intervention: Emotional Working Memory Training (EWM-T)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Working Memory Training (WM-T)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo Control
Number of subjects: 106
Study: 35609510

Group type: EXPERIMENTAL
Intervention: morphine
Number of subjects: 82

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 82
Study: 34298555

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 27564
Study: 32645765

Group type: EXPERIMENTAL
Intervention: Nitric oxide administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35343585

Group type: EXPERIMENTAL
Intervention: Carbetocin 20 μg
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Carbetocin 100 μg
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Oxytocin 0.5 IU
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Oxytocin 5 IU
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Uterine tone after 5 and 10 minutes, use of additional uterotonics, blood loss and adverse effects
Number of subjects: 277
Study: 33037142

Group type: EXPERIMENTAL
Intervention: Goal attainment scaling
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures (PROM)
Number of subjects: 229
Study: 35834633

Group type: EXPERIMENTAL
Intervention: BSRGE extract (30 mg of GABA per day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 34228017

Group type: EXPERIMENTAL
Intervention: COMprehensive Post-Acute Stroke Services intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 35869719

Group type: EXPERIMENTAL
Intervention: Propofol combined with remifentanil
Number of subjects: 126

Group type: COMPARATOR
Intervention: Propofol combined with ketamine
Number of subjects: 126
Study: 33910562

Group type: EXPERIMENTAL
Intervention: Personalized embryo transfer (pET) guided by RNA‐Seq‐based endometrial receptivity test (rsERT)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Conventional embryo transfer (ET)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Personalized embryo transfer (pET) guided by rsERT
Number of subjects: 142
Study: 35961842

Group type: EXPERIMENTAL
Intervention: Reflexology treatment along with usual medical care
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 20